kabutan

Fuso Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 34%, Oct-Dec Ordinary Profit Decreases by 9%

Thu Feb 12, 2026 3:30 pm JST Earnings

4538 Fuso Pharmaceutical Industries,Ltd. 【J-GAAP】

Earnings Report

Fuso Pharmaceutical Industries,Ltd. <4538> [TSE Prime] announced its financial results after the market closed on February 12th (15:30). The ordinary profit (non-consolidated) for the cumulative third quarter of the fiscal year ending March 2026 (April to December) dropped 33.7% from the same period last year to 2.21 billion yen. Progress toward the full-year plan of 3.30 billion yen was 67.2%, also falling below the five-year average of 96.7%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the ordinary profit for the January to March period (4Q) is expected to surge 2.5 times that of the same period last year, reaching 1.08 billion yen.

In the most recent three-month period, from October to December (3Q), the ordinary profit decreased to 1.08 billion yen, a 9.4% decrease compared to the same period last year. The operating profit margin worsened from 7.1% in the same period last year to 6.6%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 42,830 1,843 1,829 1,227 141.9 97.9 Feb 13, 2024 J-GAAP
Apr - Dec, 2024 46,659 3,633 3,341 2,402 281.3 88.4 Feb 10, 2025 J-GAAP
Apr - Dec, 2025 48,265 2,367 2,216 1,684 197.2 67.2 Feb 12, 2026 J-GAAP
YoY +3.4% -34.8% -33.7% -29.9% -29.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 30,824 1,697 1,637 -4,823 -564.7 42 May 9, 2025 J-GAAP
Oct - Mar, 2025 Guidance 30,271 2,153 2,169 1,469 172.1 45 Nov 10, 2025 J-GAAP
YoY -1.8% +26.9% +32.5% － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 55,407 1,964 1,868 1,377 160.0 70 May 10, 2024 J-GAAP
Mar, 2025 60,563 4,131 3,780 -3,288 -385.0 82 May 9, 2025 J-GAAP
Mar, 2026 Guidance 61,500 3,400 3,300 2,300 269.4 90 May 9, 2025 J-GAAP
YoY +1.5% -17.7% -12.7% － －

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 16,920 1,199 1,198 867 101.5 7.1 Feb 10, 2025 J-GAAP
Jan - Mar, 2025 13,904 498 439 -5,690 -666.2 3.6 May 9, 2025 J-GAAP
Apr - Jun, 2025 15,503 596 647 462 54.1 3.8 Aug 8, 2025 J-GAAP
Jul - Sep, 2025 15,726 651 484 369 43.3 4.1 Nov 10, 2025 J-GAAP
Oct - Dec, 2025 17,036 1,120 1,085 853 99.9 6.6 Feb 12, 2026 J-GAAP
YoY +0.7% -6.6% -9.4% -1.6% -1.6%

Related Articles